Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis

Although frequently used as a primary endpoint, disease-free survival has not been validated as a surrogate for overall survival in early breast cancer. We investigated this surrogacy in the adjuvant setting of treatment with anti-HER2 antibodies. In a systematic review and meta-analysis, we identif...

Full description

Saved in:

Bibliographic Details
Published in:	The lancet oncology Vol. 20; no. 3; pp. 361 - 370
Main Authors:	Saad, Everardo D, Squifflet, Pierre, Burzykowski, Tomasz, Quinaux, Emmanuel, Delaloge, Suzette, Mavroudis, Dimitris, Perez, Edith, Piccart-Gebhart, Martine, Schneider, Bryan P, Slamon, Dennis, Wolmark, Norman, Buyse, Marc
Format:	Journal Article
Language:	English
Published:	England Elsevier Ltd 01.03.2019 Elsevier Limited
Subjects:	Ado-Trastuzumab Emtansine - therapeutic use Antibodies, Monoclonal, Humanized - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bibliographic literature Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - genetics Breast Neoplasms - pathology Cancer therapies Chemotherapy Chemotherapy, Adjuvant - adverse effects Clinical trials Disease-Free Survival Drug Administration Schedule ErbB-2 protein Female Hematology, Oncology, and Palliative Medicine Humans Immunotherapy Meta-analysis Metastases Monoclonal antibodies Neoplasm Staging Patients Pharmaceutical industry Proportional Hazards Models Receptor, ErbB-2 - genetics Survival Systematic review Targeted cancer therapy Trastuzumab Treatment Outcome
ISSN:	1470-2045, 1474-5488, 1474-5488
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!